Prognostic impact of the isocitrate dehydrogenase 1 single‐nucleotide polymorphism rs11554137 in malignant gliomas |
| |
| Authors: | Xiao‐Wei Wang MD Blandine Boisselier MSc Marta Rossetto MD Yannick Marie PhD Ahmed Idbaih MD PhD Karima Mokhtari MD Konstantinos Gousias MD Khê Hoang‐Xuan MD PhD Jean‐Yves Delattre MD Matthias Simon MD Marianne Labussière PharmD PhD Marc Sanson MD PhD |
| |
| Affiliation: | 1. CRICM, Pierre and Marie Curie University, Paris, France;2. INSERM U 975, Paris, France;3. UMR 7225, CNRS, Paris, France;4. Genotyping and Sequencing Platform, ICM, Paris, France;5. Department of Neurology, Pitie‐Salpetriere Hospital, APHP, Paris, France;6. R. Escourolle Laboratory of Neuropathology, Pitie‐Salpetriere Hospital, APHP, Paris, France;7. Department of Neurosurgery, University Clinic Bonn, Bonn, Germany;8. Department of Neurology, Pitie‐Salpetriere Hospital, APHP, Paris, FranceFax: (011) 33 1 42 16 03 75 |
| |
| Abstract: | BACKGROUND. The IDH1 gene, which encodes isocitrate dehydrogenase 1, is frequently mutated in gliomas and acute myeloid leukemia. The single‐nucleotide polymorphism (SNP) (reference SNP no. rs11554137:C>T) located on IDH1 codon 105 has been associated with a poor outcome in patients with acute myeloid leukemia but has not been investigated in patients with gliomas. METHODS. The IDH1 codon 105 SNP was genotyped first in a series of 952 patients with grade 2 through 4 gliomas and was correlated with outcomes and tumor genomic profile. Then, it was genotyped in 2 validations sets of 306 patients with glioblastoma (GBM) and 591 patients with glioma. RESULTS. The minor allele codon 105 glycine (GGT) SNP (IDH1105GGT) was identified in 98 of 952 patients (10.3%) and was not associated with the codon 132 (IDH1132) mutation. Patients who had GMB with the IDH1105GGT variant had a poorer outcome than patients without the variant (median overall survival [OS], 10.7 months vs 15.5 months; P = .001; median progression‐free survival [PFS], 6.4 months vs 8.5 months; P = .003). The prognostic impact was confirmed in an independent validation set of 306 GBMs from the same center (median PFS, 6.8 months vs 9.7 months; P = .006; median OS, 13.9 months vs 18.8 months; P = .0187). In the second validation cohort (591 grade 2‐4 gliomas), a significant association was observed between IDH1105GGT and an adverse prognosis for the overall series and for patients with World Health Organization grade 3 gliomas, but the difference did not reach significance in patients with GBM. CONCLUSIONS. Taken together, the current data strongly suggested an association between the SNP rs11554137:C>T polymorphism and adverse outcomes in patients with malignant glioma. A single‐nucleotide polymorphism (SNP) located on codon 105 of the isocitrate dehydrogenase 1 (IDH1) gene (reference SNP rs11554137) is analyzed in 3 independent series of patients with gliomas. The SNP rs11554137 is independent of the occurrence of somatic mutation on IDH1 codon 132, but, per se, has a prognostic impact in malignant gliomas. Cancer 2013. © 2012 American Cancer Society. |
| |
| Keywords: | IDH1 glioma glioblastoma prognostic markers single‐nucleotide polymorphism |
|
|
